Satterlee W - Search Results

1

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, et al. Abbruzzese JL, et al. Among authors: satterlee w. J Clin Oncol. 1991 Mar;9(3):491-8. doi: 10.1200/JCO.1991.9.3.491. J Clin Oncol. 1991. PMID: 1999720 Clinical Trial.

2

Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days.

O'Rourke TJ, Brown TD, Havlin K, Kuhn JG, Craig JB, Burris HA, Satterlee WG, Tarassoff PG, Von Hoff DD. O'Rourke TJ, et al. Among authors: satterlee wg. Eur J Cancer. 1994;30A(3):417-8. doi: 10.1016/0959-8049(94)90276-3. Eur J Cancer. 1994. PMID: 8204374 Clinical Trial. No abstract available.

3

Clinical pharmacology of a novel diarylsulfonylurea anticancer agent.

Taylor CW, Alberts DS, Ketcham MA, Satterlee WG, Holdsworth MT, Plezia PM, Peng YM, McCloskey TM, Roe DJ, Hamilton M, et al. Taylor CW, et al. Among authors: satterlee wg. J Clin Oncol. 1989 Nov;7(11):1733-40. doi: 10.1200/JCO.1989.7.11.1733. J Clin Oncol. 1989. PMID: 2809686

4

Phase I clinical study of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641).

Hainsworth JD, Hande KR, Satterlee WG, Kuttesch J, Johnson DH, Grindey G, Jackson LE, Greco FA. Hainsworth JD, et al. Among authors: satterlee wg. Cancer Res. 1989 Sep 15;49(18):5217-20. Cancer Res. 1989. PMID: 2766290

5

A phase I and pharmacokinetic study of intravenous vinzolidine.

Taylor CW, Salmon SE, Satterlee WG, Robertone AB, McCloskey TM, Holdsworth MT, Plezia PM, Alberts DS. Taylor CW, et al. Among authors: satterlee wg. Invest New Drugs. 1990;8 Suppl 1:S51-7. doi: 10.1007/BF00171984. Invest New Drugs. 1990. PMID: 2380017

6

Phase I trial of sulofenur (LY186641) given orally on a daily x 21 schedule.

Brown TD, O'Rourke TJ, Kuhn JG, Craig JB, Havlin K, Burris HA 3rd, Cagnola J, Hamilton JM, Grindey GB, Satterlee WG, et al. Brown TD, et al. Among authors: satterlee wg. Anticancer Drugs. 1994 Apr;5(2):151-9. doi: 10.1097/00001813-199404000-00005. Anticancer Drugs. 1994. PMID: 8049498 Clinical Trial.

7

Kinetics of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641) in humans.

Hande KR, Kuttesch J, Hamilton M, Satterlee W, Jackson L, Grindey G, Hainsworth JD. Hande KR, et al. Among authors: satterlee w. Cancer Res. 1990 Jul 1;50(13):3910-4. Cancer Res. 1990. PMID: 2354440

8

Sequential use of indium-111 labeled monoclonal antibodies 96.5 and ZME-018 does not increase detection sensitivity for metastatic melanoma.

Frontiera M, Murray JL, Lamki L, Thomas J, Satterlee W, Schmelter R, Rosenblum MG, Khazaeli MB, Unger MW, Robinson WA, et al. Frontiera M, et al. Among authors: satterlee w. Clin Nucl Med. 1989 May;14(5):357-66. doi: 10.1097/00003072-198905000-00011. Clin Nucl Med. 1989. PMID: 2656042 Clinical Trial.

9

Phase I trial of intravenous vinzolidine (LY 104208) given on a biweekly dosing schedule.

Budman DR, Kreis W, Behr J, Schulman P, Lichtman S, Allen SL, Weiselberg L, Satterlee WG, Nelson RL, Vinciguerra V. Budman DR, et al. Among authors: satterlee wg. Invest New Drugs. 1990 Aug;8(3):269-74. doi: 10.1007/BF00171836. Invest New Drugs. 1990. PMID: 2272767 Clinical Trial.

10

Dermal uptake of technetium-99m MDP in calcinosis cutis.

Larsen MJ, Adcock KA, Satterlee WG. Larsen MJ, et al. Among authors: satterlee wg. Clin Nucl Med. 1985 Nov;10(11):780-2. doi: 10.1097/00003072-198511000-00006. Clin Nucl Med. 1985. PMID: 4075669

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

26 results

Search Page